Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 13.51%

Amoy Diagnostics Co., Ltd. Return on Assets (ROA) is 13.51% for the year ending December 31, 2023, a -15.41% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Amoy Diagnostics Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 15.98%, a 1.35% change year over year.
Amoy Diagnostics Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 15.76%, a 13.01% change year over year.
Amoy Diagnostics Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 13.95%, a 7.77% change year over year.
Amoy Diagnostics Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 12.94%, a -16.39% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years